A MICROSIMULATION MODEL FOR HIGH-RISK STAGE II AND STAGE III COLON CANCER SURVIVORS FOLLOWING THE CURRENT GUIDELINES

被引：0
|
作者：
Samur, S. [1 ]
Gursel, E. [2 ,3 ]
Gu, N. Y.
Palomares, M. [3 ]
Sahinkoc, M. [4 ]
Hoban, O. [2 ]
Cuyun, Carter G. [3 ]
Ayer, T. [5 ]
Chhatwal, J. [4 ]
Parikh, A. [4 ]
Neugut, A., I [6 ]
机构：
[1] Value Analyt Labs, Chantilly, VA USA
[2] Value Analyt Labs, Boston, MA USA
[3] Exact Sci, Madison, WI USA
[4] Harvard Med Sch, Boston, MA USA
[5] Georgia Inst Technol, Atlanta, GA USA
[6] Columbia Univ, New York, NY USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P59
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [41] Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer
    Cakar, B.
    Varol, U.
    Junushova, B.
    Muslu, U.
    Oner, P. Gursoy
    Surmeli, Z. Gokhan
    Cirak, Y.
    Karaca, B.
    Sezgin, C.
    Karabulut, B.
    Uslu, R.
    JOURNAL OF BUON, 2013, 18 (02): : 372 - 376
  • [42] Tumor budding as an index to identify high-risk patients with stage II colon cancer
    Nakamura, Takatoshi
    Mitomi, Hiroyuki
    Kanazawa, Hideki
    Ohkura, Yasuo
    Watanabe, Masahiko
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 568 - 572
  • [43] Identification of High-Risk Stage II and Stage III Colorectal Cancer by Analysis of MMP-21 Expression
    Wu, Tao
    Li, Yi
    Liu, Xiaohong
    Lu, Jianguo
    He, Xianli
    Wang, Qing
    Li, Jipeng
    Du, Xilin
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (07) : 787 - 791
  • [44] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Mima, Kosuke
    Miyanari, Nobutomo
    Kosumi, Keisuke
    Tajiri, Takuya
    Kanemitsu, Kosuke
    Takematsu, Toru
    Inoue, Mitsuhiro
    Mizumoto, Takao
    Kubota, Tatsuo
    Baba, Hideo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 903 - 912
  • [45] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Kosuke Mima
    Nobutomo Miyanari
    Keisuke Kosumi
    Takuya Tajiri
    Kosuke Kanemitsu
    Toru Takematsu
    Mitsuhiro Inoue
    Takao Mizumoto
    Tatsuo Kubota
    Hideo Baba
    International Journal of Clinical Oncology, 2021, 26 : 903 - 912
  • [46] MULTIPLE HIGH-RISK FEATURES IN STAGE II COLON CARCINOMA PORTEND WORSE SURVIVAL THAN STAGE III DISEASE.
    Herritt, B. C.
    Castellucci, C.
    Hajirawala, L.
    Yi, Y.
    Klinger, A.
    Orangio, G. R.
    Davis, K.
    Barton, J. S.
    DISEASES OF THE COLON & RECTUM, 2021, 64 (05)
  • [47] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089
    Haller, DG
    Catalano, PJ
    Macdonald, JS
    O'Rourke, MA
    Frontiera, MS
    Jackson, DV
    Mayer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8671 - 8678
  • [48] Chemoradiotherapy for high-risk stage II laryngeal cancer
    Satoshi Hamauchi
    Tomoya Yokota
    Yusuke Onozawa
    Hirofumi Ogawa
    Tsuyoshi Onoe
    Tomoyuki Kamijo
    Yoshiyuki Iida
    Tetsuro Onitsuka
    Hirofumi Yasui
    International Journal of Clinical Oncology, 2020, 25 : 1596 - 1603
  • [49] Chemoradiotherapy for high-risk stage II laryngeal cancer
    Hamauchi, Satoshi
    Yokota, Tomoya
    Onozawa, Yusuke
    Ogawa, Hirofumi
    Onoe, Tsuyoshi
    Kamijo, Tomoyuki
    Iida, Yoshiyuki
    Onitsuka, Tetsuro
    Yasui, Hirofumi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (09) : 1596 - 1603
  • [50] The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients
    Lonardi, S.
    Pietrantonio, F.
    Llavero, N. Tarazona
    Viladot, C. Montagut
    Bianchi, A. Sartore
    Zampino, M. G.
    Fernandez, M. E. Elez
    Vivas, C. Santos
    Mandala, M.
    Tamberi, S.
    Sciallero, M. S.
    Munoz, S.
    Lazzari, L.
    Luraghi, P.
    Torri, V.
    Cervantes, A.
    Bardelli, A.
    Tabernero, J.
    Siena, S.
    Marsoni, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1268 - S1269
12345